About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

PRISM BioLab Co.,LTD(206A) Summary

206A
TSE Growth
PRISM BioLab Co.,LTD
222
JPY
-10
(-4.31%)
Apr 9, 3:30 pm JST
1.52
USD
Apr 9, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
2.44
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 9, 2025
Opening Apr 9, 9:01 am
224 JPY 1.53 USD
Previous Close Apr 8
232 JPY 1.57 USD
High Apr 9, 11:24 am
229 JPY 1.57 USD
Low Apr 9, 12:30 pm
216 JPY 1.48 USD
Volume
220,900
Trading Value
0.05B JPY 0.34M USD
VWAP
223.61 JPY 1.54 USD
Minimum Trading Value
22,200 JPY 152 USD
Market Cap
8.12B JPY 0.06B USD
Number of Trades
231
Liquidity & Number of Trades
As of Apr 9, 2025
Liquidity
High
1-Year Average
1,273
1-Year High Jul 3, 2024
19,087
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 0 1,302,700
Mar 28, 2025 0 1,442,200
Mar 21, 2025 0 1,488,900
Mar 14, 2025 0 1,493,000
Mar 7, 2025 0 1,542,300
Company Profile
PRISM BioLab Co., LTD engages in the research and development of new drugs using its proprietary drug discovery platform (PepMetics technology).
Sector
Pharmaceuticals
PRISM BioLab is a research and development-oriented venture company focusing on drug discovery utilizing its proprietary PepMetics technology platform. The company is dedicated to creating small molecule drugs targeting intracellular protein-protein interactions (PPIs). By leveraging its unique compound library and synthesis techniques, PRISM BioLab has overcome the challenges associated with traditional approaches, which often resulted in large molecular weight compounds with potential side effects. The company's innovative small molecule compounds have successfully cleared these hurdles, enabling the development of PPI inhibitors. PRISM BioLab has multiple pipelines, including Wnt inhibitors and translation control agents, and pursues both in-house development and collaborative projects with pharmaceutical companies. By pioneering the new drug discovery field of intracellular PPIs, PRISM BioLab aims to create innovative pharmaceuticals for diseases that currently lack effective treatments.